NEW YORK — Teva Pharmaceutical Industries Ltd. has closed its acquisition of the Allergan plc generics business.

The companies said Tuesday that under the deal, announced last July, Allergan receives $33.4 billion in cash and 100.3 million shares of Teva stock, valued at $5.4 billion based on the opening price of $53.39 for Teva shares on Aug. 2. The Federal Trade Commission cleared the transaction last week.

Teva chief executive officer Erez Vigodman

With the nearly $39 billion acquisition, Teva adds Allergan’s legacy Actavis Global Generics business, including the U.S. and international generic commercial units, third-party supplier Medis, global generic manufacturing operations, and the global generic R&D unit, as well as Allergan’s international over-the-counter commercial unit — excluding OTC eye care products — and certain international brands.

Teva now has a commercial presence in 80 markets, including a top-three leadership position in more than 40 markets. The company said that, with the acquisition, it has 338 product registrations pending Food and Drug Administration approvals and holds the leading position in first-to-file opportunities, with 115 pending ANDAs in the United States. Globally, Teva plans 1,500 generic launches in 2017.

“The acquisition of Actavis Generics comes at a time when Teva is stronger than ever — in both our generics and specialty businesses,” Erez Vigodman, president and chief executive officer of Teva, said in a statement. “Through our acquisition of Actavis Generics, we are creating a new Teva with a strong foundation, significantly enhanced financial profile and more diversified revenue sources and profit streams backed by strong product development engines in both generics and specialty. This is a platform that is expected to generate multiyear top-line and bottom-line growth as well as significant cash flow.”

Allergan retains its global branded pharmaceutical business, led by products in the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.

“With the divestiture of our Global Generics business, Allergan completes the most crucial step in its strategic evolution into a focused branded browth pharma leader,” stated Allergan president and CEO Brent Saunders.

Allergan said that with the divestiture of its generics business, it plans to commence a previously announced share repurchase program, authorized for up to $10 billion by its board, in the coming days.